[go: up one dir, main page]

EP2419735A1 - Procédé pour déterminer l'expression de cbl-b - Google Patents

Procédé pour déterminer l'expression de cbl-b

Info

Publication number
EP2419735A1
EP2419735A1 EP10714250A EP10714250A EP2419735A1 EP 2419735 A1 EP2419735 A1 EP 2419735A1 EP 10714250 A EP10714250 A EP 10714250A EP 10714250 A EP10714250 A EP 10714250A EP 2419735 A1 EP2419735 A1 EP 2419735A1
Authority
EP
European Patent Office
Prior art keywords
cbl
cells
disease
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10714250A
Other languages
German (de)
English (en)
Inventor
Hans Loibner
Gottfried Baier
Günther LAMETSCHWANDTNER
Manfred Schuster
Thomas Gruber
Dominik Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Innsbruck
Universitaet Innsbruck
Apeiron Biologics AG
Original Assignee
Medizinische Universitaet Innsbruck
Universitaet Innsbruck
Apeiron Biologics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Innsbruck, Universitaet Innsbruck, Apeiron Biologics AG filed Critical Medizinische Universitaet Innsbruck
Publication of EP2419735A1 publication Critical patent/EP2419735A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Definitions

  • Cbl-b deficient mice are viable and their immune system is capable of efficiently recognizing autologous-induced tumors and building up a lytic immune response based primarily on CD8 + T cells (Loeser et al., JEM (2007) doi: 10.1084 / iem.20061699).
  • complete shutdown of the enzyme also led to an increased autoimmunity after immunization with superantigens.
  • Loeser at al. were able to demonstrate that Cbl-b is a negative regulator responsible for the "immunoreactivity" of T cells.
  • At least one antibody is suitable for determining the Cbl-b protein content in cells.
  • the cells can also be treated with other immunomodulating substances, such as cytokines or ligands of immunomodulating receptors. Therefore, preferably during or prior to detection of the binding events, the cells are treated with immunostimulating substances, preferably cytokine (s) or ligands of immunomodulating receptors, in particular TLR (toll-like receptors) or antibodies to surface molecules, in particular CD3 and / or CD28.
  • immunomodulating substances preferably cytokine (s) or ligands of immunomodulating receptors, in particular TLR (toll-like receptors) or antibodies to surface molecules, in particular CD3 and / or CD28.
  • the present invention describes for the first time a method for, for example, flow cytometric determination of the Cbl-b protein content in leukocytes and thus enables a detailed analysis of the immune status of the patient.
  • a method for, for example, flow cytometric determination of the Cbl-b protein content in leukocytes and thus enables a detailed analysis of the immune status of the patient.
  • the Cbl-b protein content in leukocytes of the patient they become isolated from patient tissue, preferably from peripheral blood, body fluids or tissue biopsies.
  • a particularly specific disease is a chronic infection.
  • the invention can be determined via Cbl-b as a biomarker, whether an immune response against a particular infection (eg contacting cells of the immune system with an antigen as described above) is sufficient to combat an infection or if there is a risk that an infection forms a chronic infection that can not be sufficiently or not successfully prevented by the immune system.
  • Example 7 therefore illustrates that the subject method for determining the Cbl-b protein content in immune cells is particularly suitable in complex immune cell mixtures with different compositions and also allows predictive statements on the response of immune cells of patients in the context of their Cbl-b content to different stimuli.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés pour déterminer la protéine Cbl-b intracellulaire dans des cellules d'un échantillon, comprenant l'introduction d'un anticorps qui lie Cbl-b de façon intracellulaire, dans une cellule, la mise en contact de l'anticorps et de protéine Cbl-b potentiellement présente dans la cellule, la détection d'événements de liaison entre l'anticorps et Cbl-b, la quantification des événements de liaison détectés, ce qui permet de déterminer la teneur en protéine Cbl-b.
EP10714250A 2009-04-14 2010-04-14 Procédé pour déterminer l'expression de cbl-b Withdrawn EP2419735A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0057309A AT508109A1 (de) 2009-04-14 2009-04-14 Verfahren zur bestimmung der cbl-b expression
PCT/EP2010/054886 WO2010119061A1 (fr) 2009-04-14 2010-04-14 Procédé pour déterminer l'expression de cbl-b

Publications (1)

Publication Number Publication Date
EP2419735A1 true EP2419735A1 (fr) 2012-02-22

Family

ID=42232619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10714250A Withdrawn EP2419735A1 (fr) 2009-04-14 2010-04-14 Procédé pour déterminer l'expression de cbl-b

Country Status (6)

Country Link
US (1) US20120040864A1 (fr)
EP (1) EP2419735A1 (fr)
AT (1) AT508109A1 (fr)
AU (1) AU2010238500A1 (fr)
CA (1) CA2758624A1 (fr)
WO (1) WO2010119061A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471548A1 (fr) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA contre la Cbl-b et optionnellement l'IL2 et l'IL12 pour l'utilisation dans le traitement du cancer
CN110044855A (zh) * 2012-02-06 2019-07-23 珀金埃尔默生物信号股份有限公司 双受体时间分辨时间分辨荧光共振能量转移法
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2008021431A2 (fr) 2006-08-14 2008-02-21 Xdx, Inc. Méthodes et compositions permettant de diagnostiquer et de surveiller l'état de rejet de greffe et de troubles immunitaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010119061A1 *

Also Published As

Publication number Publication date
US20120040864A1 (en) 2012-02-16
CA2758624A1 (fr) 2010-10-21
AT508109A1 (de) 2010-10-15
WO2010119061A1 (fr) 2010-10-21
AU2010238500A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
Delmonte et al. Flow cytometry: surface markers and beyond
Phan et al. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity
Fattorossi et al. Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment
US9291623B2 (en) Kit for identifying regulatory T cells
Richmond et al. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression
Oras et al. Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe
Newton et al. Immunophenotyping: analytical approaches and role in preclinical development of nanomedicines
Roesner et al. T‐cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin‐focused, allergen‐driven disease
US9448229B2 (en) Kit for monitoring immune status after transplant and method for monitoring immune status using same
US20200011865A1 (en) Methods and kits for detecting basophil activation
US20230349890A1 (en) Method for determination of basophil activation and kits therefore
EP2419735A1 (fr) Procédé pour déterminer l'expression de cbl-b
US20100190155A1 (en) Methods and kits for measurement of lymphocyte function
Wabnitz et al. Qualitative and quantitative analysis of the immune synapse in the human system using imaging flow cytometry
Roberts et al. Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers
Popple et al. T lymphocyte dynamics in methylisothiazolinone‐allergic patients
CN114112868B (zh) 一种用于监测肿瘤相关免疫微环境的流式细胞术试剂盒及监测方法
CA2996299C (fr) Procedes et compositions permettant la detection de l'activite de liaison au recepteur fc d'anticorps
KR102576597B1 (ko) 면역 노화 평가용 조성물 및 키트
US20240402173A1 (en) IgE+ PLASMABLASTS AS A PREDICTIVE BIOMARKER OF ALLERGY
US20240393322A1 (en) Methods for detecting heavy metals in biological samples
Vugt The search for severity predictive biomarkers in food allergy: from literature review to experimental setup
KR101349249B1 (ko) 시험관내 피부 감작성 평가 방법
Macchia et al. Optimization and intra-assay validation of a multiparametric flow cytometric test for monitoring circulating TREGs
B Dale Blood Leukocyte Characterisation in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121101